Você procurou por: spondylitis (Francês - Inglês)

ankylosing spondylitis and hl-a27.
ankylosing spondylitis and hl-a27.

the burden of ankylosing spondylitis.
the burden of ankylosing spondylitis.

b bath ankylosing spondylitis disease activity index
ed b bath ankylosing spondylitis disease activity index

high association of a hl-a antigen, w27, with ankylosing spondylitis stastnv.
high association of a hl-antigen, w27, with ankylosing spondylitis.

failure of the serological détermination of hla-b27 due to antigen masking in patients with ankylosing spondylitis schlosstein.
failure of the serological determination of hla-b27 due to antigen masking in patients with ankylosing spondylitis.

trudexa et le placebo aux semaines 2, 12 et 24 a assessments in ankylosing spondylitis b bath ankylosing spondylitis disease activity index mé
ed b bath ankylosing spondylitis disease activity index

high association of a hl-a antigen, w27, with ankylosing spondylitis stastny, 1978 : stastny p, n. engl.
high association of a hl-a antigen, w27, with ankylosing spondylitis [0346] stastny, 1978: [0347] stastny p, n. engl.

le critère principal d'efficacité (asas 20) consistait en une amélioration 20% d'au moins 3 des 4 domaines du critère asas (assessment in ankylosing spondylitis: évaluations globales par le patient, douleur dorsale, basfi, et inflammation) et à l'absence d'aggravation du domaine restant.
the primary measure of efficacy (asas 20) was a ³20% improvement in at least 3 of the 4 assessment in ankylosing spondylitis (asas) domains (patient global assessments, back pain, basfi, and inflammation) and absence of deterioration in the remaining domain.